Clinical signs associated with prostatic disorders in canines: Retrospective study in Uruguay (2011-2019).

Background: Prostate disease represents about 0.7% of diseases in canines. The main diagnosed pathology is benign prostatic hyperplasia (BPH). However, the reports that study the association of a certain clinical sign with a specific prostate disease are scarce. Aim: The main objective of this study was to evaluate the clinical relevance of the most commonly observed clinical signs associated with the different prostatic disorders in canines admitted to the hospital of the Facultad de Veterinaria-Universidad de la República between 2011 and 2019. Methods: This retrospective study included 7,729 male canines treated at the hospital de la Facultad de Veterinaria-Universidad de la República (Montevideo, Uruguay) between 2011 and 2019. 289 canines with a presumptive/definitive diagnosis of prostate diseases were selected, recording the presence/absence of associated clinical signs. Results were reported in terms of odds ratios (ORs) using logistic regression (p < 0.05). Results: The five most frequently reported clinical signs were tenesmus (34%), anorexia (32%), lethargy (27%), prostatomegaly or pain during rectal examination (25%), and abdominal pain from palpation (22%). Diarrhea (3.39 vs. 0.33 OR), anorexia (2.07 vs. 0.39 OR), weight loss (2.27 vs. 0.27 OR), hematuria (3.25 vs. 0.44 OR), and urinary incontinence (2.96 vs. 0.33 OR) indicated a highest predictive value (p < 0.05) with prostatitis versus BPH, respectively. Being weight loss, the clinical sign is more frequently associated with neoplasia (20.2 OR, p = 0.002). Conclusion: This study shows that there are clinical signs with a higher degree of association for certain canine prostatic disorders than others.

Post-castration prostatic involution: A morphometric and endocrine study of healthy canines and those with benign prostatic hyperplasia.

The objective of this study was to evaluate the effect of castration on dimensions of the prostate by B-mode ultrasound for 90 days, as well as to evaluate changes in serum concentrations of testosterone and oestradiol in clinically healthy canines and those with benign prostatic hyperplasia (BPH). Three groups of animals were used: healthy canines castrated on day 0 (HCC, n = 8), canines with a diagnosis of benign prostatic hyperplasia (BPHC, n = 9) castrated on day 0 and healthy uncastrated canines (IHCC, n = 10). Prostate size was obtained by B-mode ultrasound, while blood samples were collected (days 0, 7, 14, 28, 60 and 90 post-castration) to determine the serum testosterone and oestradiol concentration. Castration did not affect serum oestradiol concentrations. Castration led to a decrease in serum testosterone (reaching values <20 ng/dl in the first week, p < .05), causing a gradual decrease in dimensions of prostate parameters relative to body weight (p < .05). Canines with BPHC had similar prostate dimensions as the IHCC group 2 weeks post-castration. In relation to the prostate's relative parameters, the decrease with time was greater in canines with BPHC than those in the HCC group. When evaluating parameters as a percentage of relative change, the decrease with time was similar in both castrated groups, except for relative length percentage, which presented a more pronounced decline in BPHC canines than HCC canines. In conclusion, castration is an effective, fast and long-lasting treatment for canine patients with BPH, as it causes a rapid decrease in blood testosterone concentrations and a decrease in glandular volume, but does not affect serum oestradiol concentrations. This study did not determine the mechanisms of action, but allowed us to observe (based on morphometric variables) that characteristics of prostate involution after castration differed between canines with BPH and healthy canines.